Get the Stockscreener App
0.315
3.41%
0.0104
After Hours:
.33
0.015
+4.76%
Harvard Bioscience Inc stock is traded at $0.315, with a volume of 430.11K.
It is up +3.41% in the last 24 hours and down -31.37% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.3046
Open:
$0.3011
24h Volume:
430.11K
Relative Volume:
1.26
Market Cap:
$15.37M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-1.575
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
-9.40%
1M Performance:
-31.37%
6M Performance:
-87.74%
1Y Performance:
-91.15%
1-Day Range:
$0.3011
$0.3403
1-Week Range:
$0.29
$0.35
52-Week Range:
$0.29
$3.625
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.315 | 15.37M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Report Preview: W - GuruFocus
Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
What Is Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Price Doing? - Yahoo Finance
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET | HBIO Stock News - GuruFocus
Harvard Bioscience, Inc. to Announce Q1 2025 Financial Results on May 12, 2025 - Nasdaq
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at ... - Bluefield Daily Telegraph
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET - GlobeNewswire
Harvard Bioscience Sets Date for Q1 2025 Financial Results: What Investors Should Watch - Stock Titan
Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ET - IT Business Net
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)? - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Coverage Initiated at StockNews.com - American Banking and Market News
Press Release Distribution & PR Platform - ACCESS Newswire
Harvard Bioscience Inc [HBIO] Shares Rise 1.22 % on Wednesday - knoxdaily.com
Did Harvard Bioscience Inc (HBIO) perform well in the last session? - uspostnews.com
Market Watch: Harvard Bioscience Inc (HBIO)’s Noteworthy Gain, Closing at 0.40 - DWinneX
Harvard Bioscience’s Bertrand Loy to Step Down - TipRanks
Benchmark reiterates Harvard Bioscience stock with $4.50 target - Investing.com
Benchmark reiterates Harvard Bioscience stock with $4.50 target By Investing.com - Investing.com India
Harvard Bioscience’s (HBIO) Sector Weight Rating Reiterated at KeyCorp - Defense World
Harvard Bioscience (HBIO) Announces CFO Transition - GuruFocus
Harvard Bioscience Announces CFO Transition | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Sees CFO Transition with Interim Appoi - GuruFocus
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop - simplywall.st
Harvard Bioscience Appoints Mark Frost as Interim CFO - citybiz
Harvard Bioscience appoints interim CFO amid market challenges By Investing.com - Investing.com Canada
Harvard Bioscience CFO Jennifer Cote Resigns - marketscreener.com
Harvard Bioscience CFO Resignation and Interim Appointment - TipRanks
Harvard Bioscience appoints interim CFO amid market challenges - Investing.com
Harvard Bioscience Announces CFO Transition - The Manila Times
KeyBanc cuts Harvard Bioscience stock rating on financing risk By Investing.com - Investing.com Canada
Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Yahoo Finance
KeyBanc Downgrades Harvard Bioscience to Sector Weight From Overweight, Removes $3 Price Target - marketscreener.com
KeyBanc cuts Harvard Bioscience stock rating on financing risk - Investing.com
Harvard Bioscience Slides As Insider Purchases Lose Another US$76k - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $4.50 by Analysts at Benchmark - Defense World
Harvard Bioscience at KeyBanc Forum: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com South Africa
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports 2024 Financial Results - TipRanks
Harvard Bioscience Navigates Growth Amid Challenges - TipRanks
Harvard Bioscience secures waiver for credit covenant By Investing.com - Investing.com Australia
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewswire
Harvard Bioscience CEO to Host Fireside Chats at Roth and KeyBanc Healthcare Forums - StockTitan
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):